What are the dosing recommendations for heparin (unfractionated heparin) in patients requiring anticoagulation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Unfractionated Heparin Dosing Recommendations for Anticoagulation

For patients requiring anticoagulation, weight-based dosing of unfractionated heparin is recommended with an initial IV bolus of 80 units/kg followed by a continuous infusion of 18 units/kg/hour, adjusted to maintain aPTT at 1.5-2.5 times control value. 1

Dosing Regimens by Indication

Venous Thromboembolism (VTE)

  • Initial dosing options:
    • Weight-based: 80 units/kg IV bolus followed by 18 units/kg/hour continuous infusion 1
    • Fixed dose: 5,000 units IV bolus followed by at least 32,000 units/day continuous infusion 1
  • Subcutaneous administration options (if IV not feasible):
    • Initial IV bolus of 5,000 units followed by 250 units/kg SC twice daily 1
    • Initial SC dose of 333 units/kg followed by 250 units/kg SC twice daily 1

Acute Coronary Syndromes

  • Unstable angina/NSTEMI:
    • 60-70 units/kg IV bolus (maximum 5,000 units) followed by 12-15 units/kg/hour infusion (maximum 1,000 units/hour) 1
  • STEMI with fibrinolytic therapy:
    • 60 units/kg IV bolus (maximum 4,000 units) followed by 12 units/kg/hour infusion (maximum 1,000 units/hour) 1

Mechanical Heart Valves

  • 5,000 units IV bolus followed by 32,000 units/24 hours continuous infusion 2

Monitoring and Dose Adjustment

Target aPTT Range

  • Maintain aPTT at 1.5-2.5 times control value 1
  • This corresponds to a heparin level of 0.2-0.4 U/mL by protamine titration or anti-factor Xa level of 0.3-0.7 U/mL 1

Dose Adjustment Protocol

  • aPTT <35 seconds (<1.2× control): 80 U/kg bolus; increase infusion rate by 4 U/kg/hour 1, 2
  • aPTT 35-45 seconds (1.2-1.5× control): 40 U/kg bolus; increase infusion rate by 2 U/kg/hour 1, 2
  • aPTT 46-70 seconds (1.5-2.3× control): No change (therapeutic range) 1, 2
  • aPTT 71-90 seconds (2.3-3× control): Decrease infusion rate by 2 U/kg/hour 1, 2
  • aPTT >90 seconds (>3× control): Stop infusion for 1 hour, then decrease rate by 3 U/kg/hour 1, 2

Monitoring Schedule

  • Check baseline coagulation status (aPTT, INR, platelet count) 3
  • First aPTT check 6 hours after starting infusion 2
  • Continue monitoring approximately every 4-6 hours until stable, then at appropriate intervals 3
  • For subcutaneous administration, check aPTT 4-6 hours after injection 1
  • Monitor platelet count regularly to detect heparin-induced thrombocytopenia 1

Special Considerations

Pediatric Dosing

  • Initial dose: 75-100 units/kg IV bolus over 10 minutes 3
  • Maintenance dose:
    • Infants: 25-30 units/kg/hour (infants <2 months have highest requirements)
    • Children >1 year: 18-20 units/kg/hour 3

Renal Impairment

  • Consider unfractionated heparin over LMWH in severe renal impairment 1
  • Monitor more frequently for accumulation and bleeding risk 1

Obesity

  • Weight-based dosing is particularly important in obese patients to ensure adequate anticoagulation 1

Duration of Therapy

  • For VTE: Minimum 5 days, overlapping with oral anticoagulants 1
  • Continue heparin until INR is therapeutic (2.0-3.0) for at least 24 hours if transitioning to warfarin 1

Potential Complications and Pitfalls

Bleeding Risk

  • Risk increases with higher doses, concomitant use of fibrinolytics or antiplatelet agents, recent surgery, trauma, or invasive procedures 1
  • Higher risk in patients >60 years, with hepatic dysfunction, or multiple comorbidities 1

Heparin Resistance

  • May occur in inflammatory states with elevated acute phase reactants, especially fibrinogen 1
  • Consider anti-Xa monitoring rather than aPTT in these cases 1

Heparin-Induced Thrombocytopenia (HIT)

  • Monitor platelet count regularly throughout therapy 1
  • If HIT is suspected, discontinue heparin immediately and switch to a non-heparin anticoagulant 1

Weight-based dosing protocols have been shown to achieve therapeutic anticoagulation more rapidly and with fewer complications than fixed-dose regimens, leading to lower rates of recurrent thromboembolism 1. The appropriate dosing strategy should be selected based on the specific indication, patient characteristics, and clinical setting.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Anticoagulation Management for Mechanical Mitral Valves

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.